Floatz logo

Tas-102

Head and Neck Carcinoma

National Cancer Institute (NCI)unclassifiedPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

37 Active assets in the Head and Neck Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
National Cancer Institute (NCI)
Phase 2BB
Tadalafil
University of California, San Diego
Phase 2B
Rain-32
Rain Oncology Inc
Phase 2CCC
Ulixertinib
National Cancer Institute (NCI)
Phase 2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2CCC

View all 43 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →